Perceptive Advisors Llc Purchases 200,000 Shares of Athenex Inc (NASDAQ:ATNX) Stock

Athenex Inc (NASDAQ:ATNX) major shareholder Perceptive Advisors Llc acquired 200,000 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were acquired at an average price of $11.24 per share, for a total transaction of $2,248,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Perceptive Advisors Llc also recently made the following trade(s):

  • On Monday, September 14th, Perceptive Advisors Llc bought 1,800,000 shares of Athenex stock. The shares were acquired at an average cost of $11.00 per share, for a total transaction of $19,800,000.00.

Shares of NASDAQ ATNX opened at $12.55 on Wednesday. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.24 and a quick ratio of 2.77. The stock’s fifty day moving average price is $11.56 and its two-hundred day moving average price is $10.86. Athenex Inc has a one year low of $5.63 and a one year high of $18.35. The firm has a market cap of $966.81 million, a price-to-earnings ratio of -8.54 and a beta of 0.92.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.19). Athenex had a negative net margin of 82.63% and a negative return on equity of 73.35%. On average, equities analysts anticipate that Athenex Inc will post -1.76 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on the company. Zacks Investment Research raised Athenex from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Thursday, May 28th. Oppenheimer assumed coverage on Athenex in a report on Sunday, June 7th. They set a “buy” rating and a $23.00 target price on the stock. Royal Bank of Canada boosted their target price on Athenex from $31.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. BidaskClub raised Athenex from a “sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Athenex in a report on Monday, June 22nd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Athenex currently has an average rating of “Buy” and an average target price of $25.40.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC lifted its holdings in Athenex by 49.9% during the second quarter. Schonfeld Strategic Advisors LLC now owns 196,234 shares of the company’s stock worth $2,700,000 after acquiring an additional 65,296 shares during the period. Principal Financial Group Inc. raised its position in Athenex by 142.8% during the 2nd quarter. Principal Financial Group Inc. now owns 28,714 shares of the company’s stock valued at $395,000 after purchasing an additional 16,889 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Athenex by 8.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 378,124 shares of the company’s stock valued at $5,203,000 after purchasing an additional 30,684 shares during the last quarter. California State Teachers Retirement System raised its position in Athenex by 7.6% during the 2nd quarter. California State Teachers Retirement System now owns 111,000 shares of the company’s stock valued at $1,527,000 after purchasing an additional 7,869 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in Athenex during the 2nd quarter valued at approximately $257,000. 55.75% of the stock is currently owned by institutional investors.

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

See Also: The benefits and drawbacks of dollar cost averaging

Insider Buying and Selling by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.